Appie Ananas

@Jpath5211591 @RNAiAnalyst That’s possible. But building a gen2 candidate before first human data can also reflect platform maturation. If AX-0810 shows: • target engagement • biomarker effects • acceptable safety Axiomer may still validate even if potency improves later.

@AppieAnanas @RNAiAnalyst You are underestimating the importance of editing efficiency; they are pursuing a second generation version to improve efficiency which may be a red flag for the upcoming read out.

Savage! Just as $WVE and $BEAM have made their celebratory laps, in comes $krro with a real genome editing alternative for AATD: 90% RNA editing (in mice) possibly working out as something similar in the clinic with monthly dosing. Capitalism working for patients. Good.

@SteveMartihpon No one knows it, until we know it. AX-810 results will tell more.

@AppieAnanas 2/Many are trying to compare $PRQR to $WVE $BEAM $KRRO and I believe they’re doing a disservice by misleading investors. I’d love to see an”X debate” with you and some (mainly one)the ProQR bashers. Today’s update does that and clearly separates your understanding from the others

1/ Another important scientific presentation from $PRQR just dropped, this time focused on PNPLA3 and MASH/MASLD. And strategically, this may be one of the clearest examples yet of what ProQR is trying to build with Axiomer.

ProQR seems increasingly focused on proving that RNA editing can become more than a rare disease tool. The long-term vision appears to be: programmable metabolic and functional biology through RNA engineering. $PRQR

14/ It increasingly feels like a coordinated effort to prepare the market for broader platform validation ahead of AX-0810 human data expected this quarter.

@RNAiAnalyst $KRRO potency looks impressive. But cross-comparisons between AATD and bile acid modulation may not be entirely straightforward. $PRQR core bet appears to be that limited editing can still drive meaningful pathway modulation. The upcoming human AX-0810 data will be the real test.

Back of envelope: $KRRO 111 achieves 90% instead of 50% editing in mice at 1/3 of the dose that $WVE 006 did. At least 3 years behind, but a very meaningful step-up for #RNAediting in AATD. $PRQR

@Kerny13402791 Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027 ProQR expects to deliver multiple clinical data readouts across its pipeline within its current cash runway, which extends into mid-2027. proqr.com/press-releases…

@AppieAnanas $prqr future may be bright but soon they have to do an ugly raise to fund all the science...

1/ $PRQR just released two new scientific presentations (TIDES USA + ASGCT) and together they paint a bigger picture for the Axiomer RNA editing platform

@SteveMartihpon Everything comes back to AX-810

@AppieAnanas Great summary. I appreciate your hard work & insight, Thanks Extremely BULLISH on $PRQR